Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

8581. Follow-up in lung cancer: how often and for what purpose?

Follow-up in lung cancer: how often and for what purpose? Follow-up in lung cancer: how often and for what purpose? Follow-up in lung cancer: how often and for what purpose? Younes R N, Gross J L, Deheinzelin D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Two different approaches to the follow-up of patients who had undergone complete resection of non-small-cell lung cancer (NSCLC) were studied. The approaches were strict versus symptom follow-up. Strict follow-up comprised frequent visits, imaging and laboratory examinations (physical examinations, chest radiographs, CT scans and liver function tests). Symptom follow-up comprised less frequent visits (3 or less consultations per year) that were scheduled on the basis

NHS Economic Evaluation Database.1999

8582. Postoperative management of stage II/III colon cancer: a decision analysis

Postoperative management of stage II/III colon cancer: a decision analysis Postoperative management of stage II/III colon cancer: a decision analysis Postoperative management of stage II/III colon cancer: a decision analysis Michel P, Merle V, Chiron A, Ducrotte P, Paillot B, Hecketsweiler P, Czernichow P, Colin R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Different management strategies (7 in total) for patients with stage II or III resected colon cancer. Strategy 1 (S1) included adjuvant chemotherapy for patients after curative resection of stage III colon cancer and follow-up of patients with both stage II or III colon cancers. The other six strategies (described below) were variations of this strategy

NHS Economic Evaluation Database.1999

8583. Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment

Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment Domiciliary treatment of febrile episodes in cancer patients: a prospective randomized trial comparing oral versus parenteral empirical antibiotic treatment Minotti V, Gentile G (...) domiciliary treatment of febrile episodes in low-risk neutropenic and nonneutropenic patients with cancer. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with cancer who were defined as being low-risk neutropenic or nonneutropenic. Study inclusion criteria were: fever (at least 38 degrees C) on two measurements, lasting no more than 24 hour and judged to be of infectious origin; and residency within 20 miles

NHS Economic Evaluation Database.1999

8584. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK

Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK Nuijten M, Meester L, Waibel F, Wait S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Letrozole in the treatment of advanced breast cancer in postmenopausal women in the United Kingdom (UK). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The analysis involved a hypothetical cohort of patients who were identical to patients recruited from a clinical

NHS Economic Evaluation Database.1999

8585. A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes

A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes A cost-effectiveness analysis of axillary node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary (...) nodes Orr R K, Col N F, Kuntz K M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Axillary lymph node dissection in postmenopausal women with estrogen receptor-positive breast cancer and clinically negative axillary nodes. Type

NHS Economic Evaluation Database.1999

8586. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance

Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance Orr J W, Orr P, Kern D H Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of cytoreductive surgery, followed by chemotherapy directed by an in vitro assay for drug resistance. Women with advanced ovarian cancer were given surgery (including hysterectomy

NHS Economic Evaluation Database.1999

8587. Breast cancer screening by mammography in Norway: is it cost-effective?

Breast cancer screening by mammography in Norway: is it cost-effective? Breast cancer screening by mammography in Norway: is it cost-effective? Breast cancer screening by mammography in Norway: is it cost-effective? Norum J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) of effectiveness (intention to treat or treatment completers only) was not explicitly reported. The health outcome measures were the rate of recall mammography (subdivided into recall due to clinical findings, technical difficulties, and/or suspected cancer on mammography), cases of breast cancer revealed, the rate of false positives, the size of tumours, the proportion of breast cancer patients having axillary lymph node metastases, the proportion of breast cancer patients undergoing breast conserving

NHS Economic Evaluation Database.1999

8588. The cost effectiveness of tamoxifen in the prevention of breast cancer

The cost effectiveness of tamoxifen in the prevention of breast cancer The cost effectiveness of tamoxifen in the prevention of breast cancer The cost effectiveness of tamoxifen in the prevention of breast cancer Noe L L, Becker R V, Gradishar W J, Gore M, Trotter J P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of tamoxifen, 10 mg twice daily, was compared with placebo for the prevention of breast cancer. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis Study population The patient population comprised women considered to be at increased risk of developing breast cancer. These include all women aged 60 years or older, or those aged 35 to 59 years with a history

NHS Economic Evaluation Database.1999

8589. Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B

Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients: no significant difference between granulocyte-colony stimulating growth factor or ciprofloxacin plus amphotericin B Prevention of febrile leucopenia after chemotherapy in high-risk breast cancer patients (...) drawn. Health technology The use of recombinant human granulocyte-colony stimulating growth factor (rhG-CSF) or ciprofloxacin and amphotericin B (CAB) in the prevention of febrile leucopenia (FL) after high-dose chemotherapy for metastatic breast cancer. Chemotherapy comprised cyclophosphamide, 5-fluorouracil (5-FU) plus epirubicin or methotrexate (the doses were reported). Group I received rhG-CSF 263 microg subcutaneously, once daily, on days 3 to 12. Group II received 500-mg (2 x 250 mg) oral

NHS Economic Evaluation Database.1999

8590. Economic impact of automated primary screening for cervical cancer

Economic impact of automated primary screening for cervical cancer Economic impact of automated primary screening for cervical cancer Economic impact of automated primary screening for cervical cancer Smith B L, Lee M, Leader S, Wertlake P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology Automated primary screening for cervical cancer. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population Hypothetical cohort of 100,000 women aged 18 with the potential for cervical cancer and other disease based on reported US population statistics. Setting Hospital. The study was carried out in the USA. Dates to which data relate Effectiveness data were collected from studies previously

NHS Economic Evaluation Database.1999

8591. Whole-body pet imaging with (18F) fluorodeoxyglucose in management of recurrent colorectal cancer

Whole-body pet imaging with (18F) fluorodeoxyglucose in management of recurrent colorectal cancer Whole-body pet imaging with (18F) fluorodeoxyglucose in management of recurrent colorectal cancer Whole-body pet imaging with (18F) fluorodeoxyglucose in management of recurrent colorectal cancer Valk P E, Abella-Columna E, Haseman M K, Pounds T R, Tesar R D, Myers R W, Greiss H B, Hofer G A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Metabolic imaging by positron emission tomography (PET) using (18F) fluorodeoxyglucose (FDG) for the detection of recurrent colorectal cancer. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population Patients with known or suspected recurrent

NHS Economic Evaluation Database.1999

8592. Is virtual colonoscopy a cost-effective option to screen for colorectal cancer?

Is virtual colonoscopy a cost-effective option to screen for colorectal cancer? Is virtual colonoscopy a cost-effective option to screen for colorectal cancer? Is virtual colonoscopy a cost-effective option to screen for colorectal cancer? Sonnenberg A, Delco F, Bauerfeind P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology Computed tomography (CT) colonography was compared with conventional colonoscopy for screening for colorectal cancer (CRC). Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The study population comprised a hypothetical population of 100,000 individuals aged 50 years. Setting The setting was secondary care. The economic study was carried out in the Veterans

NHS Economic Evaluation Database.1999

8593. Colorectal cancer screening in Italy: feasibility and cost-effectiveness in a model area

Colorectal cancer screening in Italy: feasibility and cost-effectiveness in a model area Colorectal cancer screening in Italy: feasibility and cost-effectiveness in a model area Colorectal cancer screening in Italy: feasibility and cost-effectiveness in a model area Sorrentino D, Paduano R, Bernardis V, Piccolo A, Bartoli E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Five types of screening programmes for colorectal cancer (CRC): annual faecal occult blood testing (FOBT), sigmoidoscopy (SIGM) (every 5 years), FOBT plus SIGM (every 1 and 5 years), colonoscopy (every 10 years) (all in the age group 55-69 years, last examination at 70 years), and 'filter' colonoscopy (FC50). The latter had to be performed in persons at 50

NHS Economic Evaluation Database.1999

8594. Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer

Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer Cost-effectiveness and quality of life evaluation of ondansetron and metoclopramide for moderately emetogenic chemotherapy regimens in breast cancer Lachaine J, Laurier C, Langleben A, Vaillant L (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Ondansetron- and metoclopramide-based antiemetic regimens were compared in breast cancer patients receiving cyclophosphamide chemotherapy (moderately emetogenic). The protocol and dose

NHS Economic Evaluation Database.1999

8595. Follow up of breast cancer in primary care vs specialist care: results of an economic evaluation

Follow up of breast cancer in primary care vs specialist care: results of an economic evaluation Follow up of breast cancer in primary care vs specialist care: results of an economic evaluation Follow up of breast cancer in primary care vs specialist care: results of an economic evaluation Grunfeld E, Gray A, Mant D, Yudkin P, Adewuyi-Dalton R, Coyle D, Cole D, Stewart J, Fitzpatrick R, Vessey M Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Primary-care-centred follow up of breast cancer patients. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Women with breast cancer in remission and receiving regular follow-up. Setting Hospital and general

NHS Economic Evaluation Database.1999

8596. An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer

An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer An economic evaluation of Tomudex (raltitrexed) and 5-fluorouracil plus leucovorin in advanced colorectal cancer Groener M G, van Ineveld B M, Byttebier G, van Hout B A, Rutten F F Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Two drug therapies for the treatment of advanced colorectal cancer were studied: a combination of 5-fluorouracil (5FU) and leucovorin (LV), administered as the Mayo regimen (425 mg/m^2 5-FU and 20 mg/m^2 LV for 5 days every 4-5 weeks, (5FU+LV)), and Tomudex (raltitrexed

NHS Economic Evaluation Database.1999

8598. Brachytherapy for prostate cancer

Brachytherapy for prostate cancer Brachytherapy for prostate cancer Brachytherapy for prostate cancer Wills F, Hailey D Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wills F, Hailey D. Brachytherapy for prostate cancer. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). AHFMR HTA Report 17. 1999 Authors' objectives (...) This report aims to review the recent literature relating to the use of brachytherapy in the treatment of prostate cancer. Authors' conclusions Biochemical outcomes indicate that brachytherapy is a reasonable option for treatment of early prostate cancer in the short term, or as a boost to external beam radiation in more advanced stages. However, its potential for influencing overall outcomes, particularly long term morbidity and survival are unknown. Alternative or complementary treatments

Health Technology Assessment (HTA) Database.1999

8599. Irinotecan as second line chemotherapy in colorectal cancer

Irinotecan as second line chemotherapy in colorectal cancer Irinotecan as second line chemotherapy in colorectal cancer Irinotecan as second line chemotherapy in colorectal cancer Smithies A, Stein K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Smithies A, Stein K. Irinotecan as second line chemotherapy in colorectal cancer (...) . Southampton: Wessex Institute for Health Research and Development (WIHRD) 1999 Authors' objectives To assess the effectiveness and cost-effectiveness of irinotecan as second line chemotherapy in colorectal cancer Authors' conclusions Irinotecan is a promising new agent which appears to produce small survival gains among people with advanced colorectal cancer. The evidence in its support comes from two phase III randomised controlled trials, both of which, have some methodological problems. The Committee

Health Technology Assessment (HTA) Database.1999

8600. Predictive genetic testing for breast and prostate cancer

Predictive genetic testing for breast and prostate cancer Predictive genetic testing for breast and prostate cancer Predictive genetic testing for breast and prostate cancer Noorani H Z, McGahan L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Noorani H Z, McGahan L. Predictive genetic testing for breast and prostate cancer. Ottawa (...) : Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 1999: 85 Authors' objectives This qualitative review describes the current molecular basis of breast and prostate cancer, assesses the clinical relevance of genetic susceptibility, addresses non-directive counselling, and explores the ethical, psycho-social, and policy implications associated with genetic testing. Authors' conclusions Breast and prostate

Health Technology Assessment (HTA) Database.1999